Presented at the 45th annual San Antonio Breast Cancer Symposium® (2022 SABCS®), primary results of the multicenter international POSITIVE study…
featured news
Presented today (1) at the 45th annual San Antonio Breast Cancer Symposium® (2022 SABCS®), results of the phase II SERENA-2…
Recently published in Nature Reviews Gastroenterology & Hepatology*, a comprehensive Review focused on gastric cancer and gastro-oesophageal junction cancer (GC-GOJC)…
Recently published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), VHIO investigators have established…
Results of a study led by María Abad, Principal Investigator of VHIO’s Cellular Plasticity and Cancer Group, identify a new…
Published today, Clarivate has revealed its annual #HighlyCited2022 researchers list. Featuring among the world’s elite scientists at academic research institutes and…
Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
This is shown in the results of the CheckMate 915 study, in which Dr. Eva Muñoz-Couselo, investigator in the Breast…
Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in…
The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by…
